Clinical trials: SARS-COV2
SARS-CoV-2, Influenza
A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults
The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immunogenicity data to enable selection of an mRNA-1083 vaccine composition and dose…
- Trial name
- NCT05827926
- Testing
- Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2
- Where
- 69 sites in United States
- Volunteers
- 1,758 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
End-stage Renal Disease, SARS-CoV-2 Acute Respiratory Disease
SARS-COV-2 Screening in Dialysis Facilities
Patients receiving dialysis are one of the highest risk groups for serious illness with SARS-CoV-2 infection. In addition to the inherent risks of travel to and dialysis within indoor facilities, patients receiving dialysis are…
- Conditions
- End-stage Renal Disease, SARS-CoV-2 Acute Respiratory Disease, Dialysis; Complications
- Trial name
- NCT05225298
- Testing
- Offering SARS-CoV-2 test
- Where
- United States
- Volunteers
- 2,389 people
- Sponsor
- Stanford University
Sars-CoV2, Covid-19
Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients
The established Insight(TM) mHealth Platform, a component of the Stephenson Cancer Center (SCC) mHealth Shared Resource will be used to create the "Symptom Tracker" app.
- Trial name
- NCT04397614
- Testing
- mHealth Assessments
- Where
- United States
- Volunteers
- 128 people
- Sponsor
- University of Oklahoma
Kidney Transplant Recipients
COVID-19 Protection After Transplant Pilot Study
Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who…
- Trial name
- CPAT (NCT04969263)
- Testing
- BNT162b2 vaccine (Pfizer/BioNTech), mRNA-1273 vaccine (Moderna)
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV-2, COVID-19
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin, and to a delayed hydroxychloroquine regimen, which will serve as a…
- Trial name
- NCT04336332
- Testing
- Hydroxychloroquine Sulfate + Azithromycin, Hydroxychloroquine Sulfate
- Where
- 5 sites in United States
- Volunteers
- 75 people
- Sponsor
- Rutgers, The State University of New Jersey
COVID-19
Communities Fighting COVID Return to School
San Diego State University (SDSU), a designated Hispanic-serving institution, is partnering with Sweetwater Union High School District, an independent public school district serving 90% ethnic minority and a high proportion of…
- Trial name
- NCT05150860
- Testing
- At-home COVID-19 testing, Onsite COVID-19 testing
- Where
- United States
- Volunteers
- 852 people, healthy volunteers welcome
- Sponsor
- San Diego State University
SARS-CoV 2, COVID-19
Convalescent Plasma for Early Treatment of COVID-19
This is a double-blinded, randomized control trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma as early treatment.
- Trial name
- NCT04390503
- Testing
- Convalescent Plasma (anti-SARS-CoV-2 plasma), Control (albumin 5%)
- Where
- Brazil
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Andrew Eisenberger
Solid Tumor Malignancy, Hematologic Malignancy
A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy
Background: Coronavirus disease (COVID-19) is a viral infection. It has spread rapidly across the globe. It has overwhelmed health systems.
- Conditions
- Solid Tumor Malignancy, Hematologic Malignancy, Leukemia, Lymphoma
- Trial name
- NCT04847050
- Testing
- Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
COPD, Bronchiectasis
COmmunity Patients at Risk of Viral Infections Including SARS-CoV-2
Patients with a respiratory disease are at higher risk of poor outcomes due to worsening of symptoms caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and other respiratory infections.
- Trial name
- CORVIS (NCT04858451)
- Testing
- RESP301
- Where
- 2 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- Thirty Respiratory Limited
COVID-19, Vaccine Uptake
Addressing Vaccine Hesitancy and Increasing COVID-19 Vaccine Uptake Among African American Young Adults in the South
The study staff will conduct a hybrid type 1 effectiveness implementation 2-arm trail with 360 Black young adults from Alabama, Georgia, and North Carolina.
- Trial name
- NCT05490329
- Testing
- Tough Talks COVID
- Where
- United States
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Florida State University
SARS-CoV-2 Infection, COVID-19
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
This trial consisted of three parts, Part A, Part B, and Part C, and evaluated the safety and immunogenicity of a third (booster) injection of the multivalent vaccine BNT162b2 (B.1.1.7 + B.1.617.2), and the safety and…
- Conditions
- SARS-CoV-2 Infection, COVID-19, SARS-CoV-2 Acute Respiratory Disease, SARS (Disease)
- Trial name
- NCT05004181
- Testing
- BNT162b2, Multivalent BNT162b2 (B.1.1.7 + B.1.617.2), Monovalent BNT162b2 (B.1.1.7)
- Where
- 35 sites in United States, Germany and 2 more
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2 Infection, COVID-19
A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
This is a Phase 3, randomized, observer-blind study in healthy individuals. The primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2): As a 30-microgram dose…
- Trial name
- NCT04713553
- Testing
- BNT162b2, BNT162b2.B.1.351
- Where
- 17 sites in United States
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID 19, SARS-CoV 2
Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
The purpose of this prospective, Phase 2, multicenter, blinded, randomized placebo controlled study is to demonstrate that early treatment with mavrilimumab prevents progression of respiratory failure in patients with severe…
- Conditions
- COVID 19, SARS-CoV 2, Pneumonia
- Trial name
- NCT04399980
- Testing
- Mavrilimumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- The Cleveland Clinic
Covid19
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
- Trial name
- NCT05894577
- Testing
- Montelukast
- Where
- 109 sites in United States
- Volunteers
- 1,453 people
- Sponsor
- Susanna Naggie, MD
Covid19
ACTIV-6: COVID-19 Study of Repurposed Medications
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
- Trial name
- NCT04885530
- Testing
- Ivermectin, Fluvoxamine, Fluticasone
- Where
- 110 sites in United States
- Volunteers
- 10,956 people
- Sponsor
- Susanna Naggie, MD
Traumatic Brain Injury, Fatigue
Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
Patients with a history of mild traumatic brain injury (mTBI) or post acute sequelae of SARS-CoV-2 (PASC) and abnormal growth hormone secretion, as measured by glucagon stimulation test, will be treated with replacement growth…
- Conditions
- Traumatic Brain Injury, Fatigue, Cognitive Impairment, COVID-19
- Trial name
- NCT03554265
- Testing
- Somatropin
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Sars-CoV2
Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19
The purpose of this research is to see if Intravenous Immunoglobulin (IVIG) can help reduce respiratory complications (respiratory failure and need for a ventilator) caused by coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04411667
- Testing
- Octagam
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- George Sakoulas, MD
COVID 19, Coronavirus
A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection
The purpose of this research study is to determine if a drug called fluvoxamine can be used early in the course of the COVID-19 infection to prevent more serious complications like shortness of breath.
- Trial name
- STOP COVID (NCT04342663)
- Testing
- Fluvoxamine
- Where
- 2 sites in United States
- Volunteers
- 152 people
- Sponsor
- Washington University School of Medicine
COVID-19
Ivermectin for Severe COVID-19 Management
In this multicenter study; it was aimed to investigate the effectiveness and safety of ivermectin use in the treatment of patients with severe COVID-19 pneumonia that have no mutations which alter ivermectin metabolism and cause…
- Trial name
- NCT04646109
- Testing
- Ivermectin
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Afyonkarahisar Health Sciences University
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study
This phase I trial studies the process by which sotrovimab is absorbed, distributed, metabolized, and eliminated by the body (pharmacokinetics) in hematopoietic stem cell transplant recipients.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT05135650
- Testing
- Questionnaire Administration, Sotrovimab, Biospecimen Collection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center